Michael Saylor predicts Bitcoin is entering a bull market driven by increased involvement from banks and traditional financial institutions expanding digital asset services, especially for institutional investors. Positive regulations and growing Bitcoin custody and collateral services in the U.S. are fueling this momentum. Institutional adoption surged last year, with corporate treasuries diversifying into Bitcoin, which could push prices back into six digits if regulatory conditions remain favorable. Current price stands around $82,832, with a potential breakout depending on easing trade and foreign policy headwinds.
Michael Saylor's Bitcoin bull market outlook comes as 45 of 50 major cryptocurrencies on Pluang rose today, showing broad market strength. Notable movers include AXS at Rp18.925 with a 5.20% increase and a typical hold time of 63 days, SNX at Rp4.060 up 4.96% with 75% buy order activity, and MANA at Rp1.569 rising 4.74% despite 87% sell order activity. This snapshot is as of Oct 21, 2026 03:41 WIB.
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
